HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Nakaraang pagsara
$2.62
Sakop ng araw
$2.45 - $2.67
Sakop ng taon
$2.19 - $4.20
Market cap
21.07M USD
Average na Volume
68.29K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 5.34M | -10.53% |
Net na kita | -4.93M | 6.29% |
Net profit margin | — | — |
Kita sa bawat share | -0.59 | 9.23% |
EBITDA | -5.29M | 10.53% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 35.86M | -34.08% |
Kabuuang asset | 38.20M | -34.24% |
Kabuuang sagutin | 4.76M | -11.55% |
Kabuuang equity | 33.44M | — |
Natitirang share | 8.39M | — |
Presyo para makapag-book | 0.65 | — |
Return on assets | -33.03% | — |
Return on capital | -37.14% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -4.93M | 6.29% |
Cash mula sa mga operasyon | -2.52M | 29.72% |
Cash mula sa pag-invest | -6.30M | -151.46% |
Cash mula sa financing | 0.00 | 100.00% |
Net change in cash | -8.78M | -200.53% |
Malayang cash flow | -857.00K | 47.89% |
Tungkol
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Itinatag
1980
Headquarters
Website
Mga Empleyado
25
